Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
2ez93QLn24MteqJX
